On August 11, 2022 Oncopeptides AB (publ) (NASDAQ Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, reported for the second quarter 2022 (Press release, Oncopeptides, AUG 11, 2022, View Source [SID1234618184]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"CHMPs recommendation to grant Pepaxti a full marketing authorization approval in EU is foundational for Oncopeptides," says Jakob Lindberg, CEO of Oncopeptides. "This is excellent news for patients, shareholders, and for the future development of Oncopeptides."
Financial overview April-June
Net sales amounted to SEK 8.8 M (66.4)
Operating profit was SEK -61.1 M (-344.8)
Net profit amounted to SEK -59.8 M (-24.1)
Profit per share, before and after dilution, amounted to SEK -0.79 (-0.32)
Cash balances at the end of the period amounted to SEK 90.8M (999.4)
Financial overview January-June
Net sales amounted to SEK 8.8 M (85.7)
Operating profit was SEK -160.0 M (-692.2)
Net profit amounted to SEK -158.4 M (-258.8)
Profit per share, before and after dilution, amounted to SEK -2.10 (-3.63)
Cash balances at the end of the period amounted to SEK 90.8M (999.4)
Significant events April-June
CHMP, the European Medicines Agency´s Committee for Medicinal Products for Human Use, unanimously recommended the European Commission to grant a full marketing authorization approval of Pepaxti in the EU
Events after the period
Direct share issue raising approximately SEK 435.6 million (USD 41.1 million) before transaction costs
FDA has announced an ODAC, a public meeting with the Oncologic Drugs Advisory Committee, on September 22, to discuss benefit/risk of Pepaxto
Conference call for investors, analysts, and media
Investors, analysts, and media are invited to participate in a webcast and a following QnA session today at 14:00 (CET). The event will be hosted by CEO Jakob Lindberg, together with CMO Klaas Bakker and CFO Annika Muskantor. The presentation will be held in English.
The webcast will be streamed via View Source, and is also available on the corporate website: www.oncopeptides.com. PIN-code for participants is 4998014#
Rolf Gulliksen, Global Head of Corporate Communications, Oncopeptides AB (publ)
E-post: [email protected]
Mobil: + 46 70 262 96 28
The information in the press release is information that Oncopeptides is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact persons above, on August 11, 2022, at 08.00 (CET).